baricitinib
Lilly and Incyte’s atopic dermatitis drug shows promise at Phase 3
February 13, 2020Sales and Marketing Eli Lilly, Incyte, baricitinib, pharma
Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib …
Lilly’s arthritis drug found to prevent potentially lethal stem cell transplant complications
April 25, 2018Research and Development Cancer, Eli Lilly, JAK inhibitors, Stem cells, baricitinib, graft-versus-host disease, pharma
Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …
Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns
April 20, 2018Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
Lilly gets second shot at application for ‘blockbuster’ arthritis drug
August 31, 2017Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical
Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …
Lilly awaits FDA review of new arthritis treatment
January 20, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis
Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
